HAVCR2 and myelodysplastic syndrome: In comparison, TIM3 inhibitors have a slightly weaker ORR than PD-1 and Clever-1 inhibitors, but have a stronger overall safety profile, with no typical irAE occurring at present, and may be more suitable for MDS patients intolerant of PD-1 toxicity.TIM3 is uniquely advantageous in that it can target both T-cells and myeloid tumor cells, making it more suitable for patients with a highly suppressed immune microenvironment (e.g., high Treg infiltration).